Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2010

View Archived Issues

NVP-LDE-225: a newly discovered therapeutic candidate for Gorlin's syndrome / News in Context

Nerviano Medical Sciences discloses new pim-1 and pim-2 kinase inhibitors

Phenomix identifies new NS3 NS4A protease inhibitors for HCV infection

Merck Frosst claims new prostanoid DP2 receptor antagonists

Allergan describes novel alpha2B-adrenoceptor antagonists

Merck Frosst discloses new prostanoid EP4 receptor antagonists

Phase III data presented on sodium oxybate in fibromyalgia

Phase II/III data on tafamidis meglumine in TTR-type familial amyloid polyneuropathy

Fab-001 potently active against multiple staphylococcal strains in preclinical study

Ark begins phase I/IIa trial of high-dose VEGF-D in peripheral vascular disease

Phase Ib safety/efficacy data disclosed on SD-101 in treatment-naive hepatitis C

BioMarin launches Firdapse in Europe for Lambert-Eaton myasthenic syndrome

Shionogi and Eli Lilly launch Cymbalta in Japan for depression and depressive symptoms

Javelin terminates merger agreement with Myriad

CSL Behring receives FDA approval to extend shelf life of Privigen

Hygeia Therapeutics to advance development of topical hormone receptor modulators

Meda launches EpiCept's Ceplene in the U.K.

FDA approves BioAlliance's Oravig for oropharyngeal candidiasis

Protein Potential receives NIAID grant to develop malaria vaccine

AMRI and Navigen enter into research collaboration

Takeda obtains five NDA approvals in Japan

Gilead halts phase II trial of GS-9450 in chronic hepatitis C

GSK receives conditional marketing approval for Arzerra in Europe

Dexmedetomidine meets phase III primary endpoint in sedation of ICU patients

Prana Biotechnology set for phase IIb PBT-2 trial in Alzheimer's disease

MTD of EMD-534085 established in phase I trial in advanced solid tumors and lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...